{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-24-000018","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2024-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.746024+00:00","generated_at":"2026-06-02T23:13:30.582230+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Amneal Q1 revenue $659M (+18% YoY); GAAP net loss $92M on $94M opioid charge","bullets":["Net revenue $659M (+18% YoY); Generics +14%, Specialty +15%, AvKARE +33%.","GAAP net loss $92M ($0.30 loss per share) includes $94M pre-tax charge for nationwide opioids settlement in principle.","Adjusted EBITDA $152M (+31% YoY); adjusted diluted EPS $0.14 (vs $0.12 YoY).","Opioids settlement payable over ten years; company affirming 2024 full-year guidance.","All three segments posted double-digit revenue growth for first time in same quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-24-000018","json":"https://secwatch.observer/filing/0001723128-24-000018.json","markdown":"https://secwatch.observer/filing/0001723128-24-000018.md","text":"https://secwatch.observer/filing/0001723128-24-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312824000018/0001723128-24-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312824000018/amrx-20240503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:13:30.582230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"abc42f280d646d38f368d310c8682f587b874fec","claim":"Amneal Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: revenue $659 million, net income $92 million, EPS $0.30. Guidance reaffirmed.","evidence_excerpt":"the information furnished pursuant to Item 2.02 of this report. --- EX-99.1 (EX-99.1) --- AMNEAL REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS ‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒ ‒ Company has reached settlement in principle","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312824000018/0001723128-24-000018-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$659 million"},{"label":"Net income","value":"$92 million"},{"label":"EPS","value":"$0.30"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}